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Objective : We analyzed the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter in World Health
Organization (WHO) grade III gliomas in association with other molecular markers to evaluate their prevalence.
Methods : The samples of a total of 36 newly WHO grade III glioma patients including 19 anaplastic oligodendrogliomas (AO), 7 anaplastic
oligoastrocytomas (AOA), and 10 anaplastic astrocytomas (AA) were analyzed. The methylation status of the MGMT gene promoter was
confirmed by methylation-specific polymerase chain reaction. The 1p/19q chromosomal deletion status and EGFR amplification were assessed by
Fluorescence In-Situ Hybridization. MGMT, EGFR, EGFRvIII, and p53 expression were analyzed by immunohistochemical staining.
Results : The MGMT gene promoter was methylated in 32 (88.9%) and unmethylated in 4 (11.2%). Among them, all of the AO and AOA had
methylated MGMT gene promoter without exception. Significant associations between MGMT gene promoter hypermethylation and 1p/19q
deletion was observed (p = 0.003). Other molecular markers failed to show significant associations between MGMT gene promoter statuses.
Conclusion : There was extensive epigenetic silencing of MGMT gene in high grade gliomas with oligodendroglial component. Together with
frequent 1p/19q co-deletion in oligodendroglial tumors, this may add plausible explanations supporting the relative favorable prognosis in
oligodendroglial tumors compared with pure astrocytic tumors.
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INTRODUCTION
Anaplastic astrocytoma (AA), anaplastic oligodendro-
glioma (AO), and anaplastic oligoastrocytoma (AOA) are
classified into the histological categories of World Health
Organization (WHO) grade III gliomas, even though their
classification based on the known molecular biology in-
formation remains controversial8,9,12,17). O6-methylguanine-
DNA methyltransferase (MGMT) is an enzyme in the
DNA repair process that specifically removes cytotoxic O6-
alkylguanine adducts, thus mediating resistance to
alkylating agents16). The role of this DNA repair enzyme in
glioblastoma, that protects the tumor cells against alkylating
and methylating chemotherapeutic agents, resulting in
drug resistance is well studied18). MGMT methylation
prevalence in glioblastoma was reported to be from 30% to
50%2,6,15). However, the investigation for the prevalence of
MGMT gene promoter methylation status as well as their
clinical implication in WHO grade III glioma is sparse.
Therefore, we evaluated the methylation status of the
MGMT gene promoter in WHO grade III gliomas using




A total of 36 newly diagnosed World Health Organi-
zation (WHO) grade III glioma patients were included in
this study. Histological diagnosis according to the WHO
2007 classification was assorted AO in 19 patients, AOA in
7 patients and anaplastic astrocytoma (AA) in 10 patients.
The study population consisted of 18 men and 18 women
ranging in age from 20 to 79 years (mean, 46.6 years). All
patients underwent surgical removal or biopsy sampling of
their tumor. And, the adjuvant conventional radiotherapy
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and chemotherapy were performed after pathologic
diagnosis in all patients.
Methylation-specific polymerase chain reaction
The methylation status of the MGMT gene promoter
was confirmed by MSP. Tissue was dissected from paraffin
blocks and put into polyethylene microtubes. After depara-
ffinization with xylene and alcohol, the blocks were
dissolved in a lysis buffer solution containing proteinase K.
For the MSP, purified DNA was modified by sodium
bisulfite treatment using an EZ DNA methylation-Gold
Kit™ (Catalog No. D5005; Zymo Research, Orange, CA,
USA). The primer sequences for the MGMT were as follows
: methylated forward : 5 TTT CGA CGT TCG TAG
GTT TTC GC 3 methylated reverse : 5 GCA CTC TTC
CGA AAA CGA AAC G 3 , unmethylated forward : 5
TTT GTG TTT TGA TGT TTG TAG GTT TTT GT
3 , unmethylated reverse : 5 AAC TCC ACA CTC TTC
CAA AAA CAA AAC A 3 . The annealing temperature was
64 ˚C. The PCR products obtained were electrophoresed
in 2% agarose gels and visualized under ultraviolet illumi-
nation after staining with ethidium bromide. CpGenome
universal unmethylated (Catalog No. S7822; Chemicon,
Temecula, CA, USA) and methylated DNA sets (Catalog
No. S 7821; Chemicon) were used as negative and positive
controls respectively.
For the evaluation of the assay results, the products from
the controls were examined first. The MGMT gene
promoter fragments in the controls should be observed at
80 and 92 base pairs in the methylated DNA-methylated
primer and unmethylated DNA-unmethylated primer
combinations respectively. The methylated DNA-unme-
thylated primer and unmethylated DNA-methylated
primer controls should not show any bands. If the control
results were acceptable, patient samples were evaluated for
the presence of amplification with the methylated and
unmethylated primers. The results were interpreted as
positive if MGMT gene promoter methylation was
detected as a fragment of 80 base pairs observed on the gel,
and negative if MGMT gene promoter methylation was
not detected with the methylated primers.
Fluorescence in-situ
hybridization
The 1p/19q chromosomal deletion
status and epidermal growth factor
receptor (EGFR) amplification were
assessed by rluorescence in-situ hybri-
dization (FISH) on paraffin sections
obtained during surgery. The proce-
dure and materials are followed as previously described7). 
Immunohistochemistry
MGMT, EGFR, epidermal growth factor receptor
variant III (EGFRvIII), and p53 expression were analyzed
by immunohistochemical staining. Immunohistochemical
staining was done using the conventional labeled strep-
tavidin-biotin-peroxidase method (LSAB Kit, DAKO,
Glostrup, Denmark) according to the manufacturer’s
protocol. The used antibodies are as follows; MGMT
(Neomarkers, Fermont, CA, USA), EGFR (Zymed, San
Francisco, CA, USA), EGFRvIII (DAKO, Glostrup,
Denmark), and p53 (DAKO, Glostrup, Denmark). Im-
munohistochemistry results were semiquantitatively graded
as < 5% (negative), 5-10% (1+), or >10% (2+), based on the
percentage of tumor cells showing immunoreactivity. We
considered more than 1+ as positive for corresponding
markers.
Statistical analysis
For analyzing associations between markers, the chi-
square test was used for parametric comparisons. Statistical
significance was accepted at probability values of less than
0.05. These statistical analyses were performed with the aid of
SPSS software (version 12.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Methylation status of the MGMT gene promoter
and MGMT expression
Of the 36 patients whose samples were analyzed, the
MGMT gene promoter was methylated in 32 (88.9%) and
unmethylated in 4 (11.2%). The results according to the
histological classification is summarized in Table 1. In-
terestingly, all the high grade gliomas with oligodendroglial
component (AO or AOA) had methylated MGMT gene
promoter. Comparison with the immunohistochemistry
result revealed that 81.5% of the analyzable samples
showed matched results which include methylated MGMT
gene promoter and negative MGMT gene promoter
expression or vice versa. 
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Table 1. The prevalence of methylation status of MGMT gene promoter according to the
histological classification. Results are from the methylation-specific polymerase chain reaction
method. Numeric is number of patients
Histological diagnosis Total
MGMT gene promoter status
methylated unmethylated
Anaplastic oligodendroglioma 19 19 0
Anaplastic oligoastrocytoma 7 7 0
Anaplastic astrocytoma 10 6 4
MGMT : O6-methylguanine-DNA methyltransferase
Relationships between MGMT gene promoter
status and other molecular markers
Associations between the MGMT gene promoter meth-
ylation status and other molecular markers such as 1p/19q
deletion, EGFR amplification, EGFR expression,
EGFRvIII expression and p53 expression are summarized
in Table 2. Of 19 patients with AOs, 1p/19q co-deletion
was observed in 18 patients. And, 3 of 7 patients with
AOA revealed intact 1p/19q while the others had deletion
in either 1p or 19q. All patients with AA had intact 1p/19q
chromosome except for 2 patients who showed deletion in
1p and in 19q, respectively. Significant associations between
MGMT gene promoter hypermethylation and 1p/19q
deletion was observed (p = 0.003) which implies strong evi-
dence of MGMT gene promoter hypermethylation in high
grade oligodendroglial tumors. EGFR amplification was not
observed in any of the present series of samples and other
molecular markers failed to show significant associations
between MGMT gene promoter statuses.
Relationships between EGFR amplification by
FISH and expression of EGFR or EGFRvIII on
immunohistochemical staining
EGFR amplification was assessed by FISH in 32 available
samples and the results were negative for all cases. Of 32
samples, immunohistochemical staining was done in 30
with EGFR and 17 with EGFRvIII. Positive immumo-
reactivity was observed with EGFR in 14 (46.7%) samples
and with EGFRvIII in 13 (76.5%).
DISCUSSION
The present study clearly showed that high grade oligo-
dendroglial tumors are always hypermethylated in the MGMT
gene promoter. Only a few studies reported the status of
MGMT gene promoter methylation in gliomas other than
glioblastoma. Möllemann et al.13) reported that MGMT
hypermethylation and low or absent expression are frequent in
oligodendroglial tumors that 46 of 52 tumors (88%) showed
MGMT gene promoter hypermethylation. Among their 23
AOs and 11 AOAs, the MGMT gene promoter was not
methylated in only 1 and 2 samples respectively and those
samples showed no 1p/19q co-deletion13). Dong et al.3)
reported that the prevalence on MGMT gene promoter
hypermethylation detected by MSP analysis was 60% of 43
oligodendroglial tumors including 67% of 15 AO/AOAs.
Their data showed significant association between
hypermethylation of MGMT gene promoter and 1p/19q co-
deletion3). Alonso et al.1) also reported that as much as 80% of
41 oligodendroglial tumor samples were hypermethylated in
their MGMT gene promoter and among them, 85% of 13
AOs were hypermethylated. Contrast to the high frequency of
methylation rate of MGMT gene promoter in AO/AOAs, that
of AA was found to be relatively low that less than 50% were
methylated according to the previous studies4,5). Taken together
with the previous and the present study, transcriptional
silencing of the MGMT gene by hypermethylation in
oligodendroglial tumor especially in high grade may contribute
to the tumor’s sensitivity to chemotherapy. Nutt et al.14) showed
that the low activity of MGMT is
sufficient to account for increased
sensitivity of oligodendrocytic cells to
chemotherapeutic drugs.
There are evidences that the MG-
MT gene promoter methylation is
associated with tumor progression in
oligodendroglial tumors. The presence
of hypermethylation of MGMT in
WHO grade II astrocytoma/oligo-
dendroglioma is only 31%5). Lavon et
al.11) performed a longitudinal assess-
ment of epigenetic aberrant MGMT
gene promoter methylation with 46
paired early and progressive oligoden-
drogliomas from 23 patients, and cor-
related them with tumor phenotype
in a series of progressive oligoden-
droglial tumors. They demonstrated
that the MGMT gene promoter me-
thylation is more pronounced at
MGMT in High Grade Glioma | SH Yang, et al.
387
Table 2. The relations between MGMT gene promoter status and other molecular markers.
Numeric is number of patients
MGMT gene promoter status
Variable Methylated Unmethylated p-value
(n = 32) (n = 4)
1p/19q deletion (n = 36)
Deletion (either) 24 0 0.003
No deletion (both) 8 4
EGFR�amplification (n = 32)
Yes 0 0 NA§
No 28 4
EGFR�expression (n = 33)
Positive 13 3 0.233
Negative 16 1
EGFRvIII�expression (n = 17)
Positive 11 2 0.659
Negative 3 1
p53 expression (n = 32)
Positive 9 1 0.773
Negative 19 3
MGMT: O6-methylguanine-DNA methyltransferase, EGFR: Epidermal growth factor receptor
EGFRvIII: Epidermal growth factor receptor variant III, NA: not available
tumor progression, particularly in tumors with an intact 1p
in oligodendroglial tumors and it was postulated that the
MGMT promoter methylation is a late event in progressive
oligodendrogliomas11). It is accepted that the oligoden-
droglial tumor has a tendency to be methylated in various
gene promoters including MGMT and this may be asso-
ciated with the initiation and/or progression of oligo-
dendroglial tumors10). However, whether MGMT gene
methylation is an actual etiologic event for oligodendroglial
tumors or only a prognostic factor needs further investiga-
tion10).
CONCLUSION
Our study for MGMT gene promoter methylation status
in 36 WHO grade III gliomas revealed extensive epigenetic
silencing of MGMT gene in high grade gliomas with
oligodendroglial component. Together with frequent
1p/19q co-deletion in oligodendroglial tumors, this may
add plausible explanations supporting the relative favorable
prognosis in oligodendroglial tumors compared with pure
astrocytic tumors.
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